RAREsummit19
speaker profileDR. Ana Mingorance
Chief Development Officer of the Loulou Foundation, the Scientific Director of the Dravet Syndrome Foundation Spain
Facilitator for Moderated Panel Discussion: Patient groups partnering in the drug development process – Something for everyone
Bio: Ana Mingorance, PhD, is the Chief Development Officer of the Loulou Foundation, the Scientific Director of the Dravet Syndrome Foundation Spain, and an independent consultant in genetic epilepsy syndromes and orphan drug development.
A neuroscientist by training, Ana first worked in drug discovery and development as a laboratory head and discovery project leader at the global pharmaceutical company UCB Pharma.
She then founded her own boutique consultancy firm, Dracaena Consulting to focus on orphan neurological diseases and to work more closely with patient organizations. Ana is a strong advocate for patient involvement in drug discovery and development, and through her multiple roles, she joins forces with the patient communities to accelerate the development of new treatments.
Ana received her PhD in neuroscience from the University of Barcelona in Spain and completed an EMBO postdoctoral fellowship at the University of British Columbia in Vancouver, Canada.